Click here to download a PDF of Rick’s CV.

July, 2019


Born February 8, 1952, Los Angeles, CA

US Citizen



1969-1971    Zoology, Pomona College, Claremont, CA

1971-1973    B.S., Biological Sciences, Stanford University, Stanford CA


1973-1977    M.D., Albert Einstein College of Medicine of Yeshiva University, Bronx, NY

Postgraduate Training

1977-1978    Rotating internship, General Psychiatry, University of California Davis Medical Center, Sacramento, CA

1978-1981    Residency, General Psychiatry, University of California Davis Medical Center, Sacramento, CA

1982-1983    Fellowship, Clinical Psychopharmacology Research, University of California San Diego, La Jolla, CA

1985-1987    Clinical Associate Physician, General Clinical Research Center, University of New Mexico


1973            Departmental Honors, Biological Sciences, Stanford University, Stanford, CA

1977            Alpha Omega Alpha, Albert Einstein College of Medicine, Bronx, NY

1981            Sandoz Outstanding Graduating Resident, University of California Medical Davis Center, Sacramento, CA

1993&1994    Clinical Scientist Award, Clinical Research Center, University of New Mexico School of Medicine

1995            Research Scientist Award, Clinical Research Center, University of New Mexico School of Medicine


1984            American Board of Psychiatry and Neurology (Psychiatry)

1985-           New Mexico Medical License #85-105


1983-1984    Clinical Assistant Professor, Assistant Residency Training Director, Department of Psychiatry, University of California Davis Medical Center, Sacramento, CA

1985-1991    Assistant Professor, Department of Psychiatry, University of New Mexico School of Medicine

1991-1995    Associate Professor (tenured), Department of Psychiatry, University of New Mexico School of Medicine

1996-1999    Clinical Associate Professor of Psychiatry, University of British Columbia, Vancouver, BC

2000-           Clinical Associate Professor of Psychiatry, University of New Mexico School of Medicine

2008-           Associate Research Scientist, Bastyr University, Kenmore WA


1981-1982    Staff Psychiatrist, Fairbanks Community Mental Health Center, Fairbanks, Alaska

1981-1982    Private Practice, Psychiatry, Fairbanks, Alaska

1985            Chief of Psychiatry, University of New Mexico Cancer Research and Treatment Center

1985            Attending Psychiatrist, Alcoholism Treatment Program, Bernalillo County Mental Health Center, Albuquerque, NM

1985, 1993-1995   Attending Psychiatrist, Consultation/Liaison Service, University of New Mexico Hospital, Albuquerque, NM

1986-1992    Attending Psychiatrist, Bernalillo County Outpatient Mental Health Clinics, Albuquerque, NM

1996-1997    Staff Psychiatrist, Whatcom Counseling and Psychiatric Clinic, Bellingham, WA

1996-1997    Medical Staff, St. Joseph Hospital, Bellingham, WA

1997-2000    Staff Psychiatrist, Jefferson Mental Health Services, Port Townsend, WA

2000-2004    Private practice of psychiatry, Taos NM

2004-2006    Staff psychiatrist, Presbyterian Medical Services, Gallup, NM

2006-2008    Staff psychiatrist, Ayudantes Inc, Espanola NM


1985-1995    Medical Consultant, Veterans Administration Hospital, Albuquerque, NM

1985-1995    Medical Expert, Office of Hearing and Appeals, Social Security Administration, Albuquerque, NM

1995-2000    Medical Expert, Office of Hearing and Appeals, Social Security Administration, Seattle, WA

1999-2000     Independent Medical Examiner, CorVel Corporation, Poulsbo, WA

Various times    Consultant to National Institute on Drug Abuse, Food and Drug Administration, private industry


1985-1995    Member, Psychiatry Research Committee, University of New Mexico School of Medicine

1988-1992    Member, Scientific Advisory Committee, General Clinical Research Center, University of New Mexico School of Medicine

1989-1992    Chairman, Scientific Advisory Committee, General Clinical Research Center, University of New Mexico School of Medicine

1994-1995    Chairman, Sabbatical Committee, Department of Psychiatry, University of New Mexico School of Medicine

External dissertation reviewer

2012   Ethan McIlhenny, Louisiana State University, LA. Neuroscience

2018   Rachel Turetzky, Pacifica Graduate Institute, CA. Psychology



Addiction Research

Archives of General Psychiatry

Case Reports in Psychiatry

European Journal of Clinical Oncology

Experimental and Clinical Psychopharmacology

Frontiers in Immunology

Journal of Clinical Psychopharmacology

Journal of Endocrinological Investigation

Journal of Nervous and Mental Disease

Journal of Pineal Research

Journal of Scientific Exploration

New England Journal of Medicine


Therapeutic Advances in Psychopharmacology


Journal of Drug Education and Awareness


Journal of Mindbody States

Journal of Psychedelic Studies


Frontiers in Pharmacology: Research Topic: “Psychedelic Drug Research in the 21st Century”; 2017-2018


1985-1986    Principal Investigator, Lynn Pierson Therapeutic and Research Program, (State funded, DEA-, FDA-, NIDA-approved program to provide marijuana/THC to cancer patients for chemotherapy side effects)

1985-1987    Clinical Associate Physician, National Institute of Health, General Clinical Research Center, University of New Mexico School of Medicine, “Human Psychopharmacology of Melatonin,” Approximately $130,000 total costs

1989-1990    Principal Investigator, Scottish Rite Foundation for Schizophrenia Research, “Human Psychopharmacology and Neuroendocrinology of N, N-Dimethyltryptamine.” Approximately $30,000 total costs

1990-1992    Principal Investigator, National Institute on Drug Abuse, Small Grant (R03) Award, “Human Psychopharmacology and Neuroendocrinology of DMT,” Approximately $150,000 total costs

1993-1995    Principal Investigator, National Institute on Drug Abuse, (R01) Award, “Tryptamine Hallucinogens: Human Neuropsychopharmacology,” Approximately $350,000 total costs


Peer-reviewed journal articles
  1. Strassman RJ, Letourneau P, Wessells NK: Elongation of axons in an agar matrix that does not support cell locomotion. Experimental Cell Research 818:482-487, 1973
  2. Strassman RJ, Wessells NK: Orientational preferences shown by microspikes of growing nerve cells in Tissue and Cell 5:412-417, 1973
  3. Strassman RJ, Galanter M: The Abhidharma: A cross-cultural application of meditation. International Journal of Social Psychiatry 26:283-290, 1980
  4. Risch SC, Janowsky DS, Lisansky EJ, Strassman RJ, Rausch JL, Gillin JC, Judd LL, Huey L: Dexamethasone effects on self-rated mood in depressed   American   Journal   of   Psychiatry   141:147-148, 1984
  5. Strassman RJ: Adverse reactions to psychedelic drugs: A review of the literature. Journal of  Nervous  and  Mental  Disease  172:577-595,  1984
  6. Strassman R: Light, season, and affective Western Journal of Medicine 142:678, 1985
  7. Kennedy B, Strassman RJ, Ziegler M, Janowsky DS, Risch SC, Huey L, Gillin JC: Cardiovascular, catecholamine and psychological responses to TRH in four types of affective disorder patients. Hormone and Metabolic Research 19:164-167, 1987
  8. Strassman RJ, Peake GT, Qualls CR, Lisansky EJ: A model for the study of the acute effects of melatonin in man. Journal of Clinical Endocrinology and  Metabolism   65:847-852, 1987
  9. Rosenthal M, Strassman RJ: Melatonin does not impair corticotropin response of isolated pituitary Neuroendocrinology Letters 10:27-32, 1988
  10. Strassman RJ, Peake GT, Qualls CR, Lisansky EJ: Lack of an acute modulatory effect of melatonin on human nocturnal thyrotropin and cortisol secretion. Neuroendocrinology    48:387-393,  1988
  11. Strassman RJ, Appenzeller O, Lewy AJ, Qualls CR, Peake GT: Increase in plasma melatonin, beta-endorphin and cortisol after a high-altitude mountain run. Relationship to performance and lack of an effect of  naltrexone.  Journal  of  Clinical  Endocrinology  and  Metabolism  69:540-545, 1989
  1. Lisansky EJ, Peake GT, Strassman RJ, Qualls CR, Meikle AW, Risch SC, Fava G, Zownir-Brazis M, Hochla P, Britton D: Augmented pituitary corticotropin response to a threshold dosage of human corticotropin-releasing hormone in depressives pre-treated with metyrapone. Archives of General Psychiatry 46:641-649, 1989
  1. Strassman RJ, Qualls CR, Lisansky EJ, Peake GT: Sleep deprivation reduces LH secretion independently of melatonin. Acta Endocrinologica 124:646-651, 1991
  2. Strassman RJ, Qualls CR, Lisansky EJ, Peake GT: Elevated rectal temperature produced by all night bright light is reversed by melatonin infusion in    Journal  of  Applied  Physiology   71:2178-2182, 1991
  3. Strassman RJ: Human hallucinogenic drug research in the United States: A present-day case history and a review of the Journal of Psychoactive Drugs  23:29-38,  1991
  4. Strassman RJ: Human hallucinogen interactions with drugs affecting serotonergic neurotransmission. Neuropsychopharmacology 7:241-243;  1992
  5. Lisansky EJ, Hauger R, Strassman RJ, Dorin R, Meikle AW, Brazis M, Qualls CR, Turkin A. Beta-endorphin response to a low dosage of human corticotropin releasing hormone during metyrapone administration in depression. Endocrinology Research  18:241-260,
  6. Strassman RJ, Qualls CR. Dose-response study of N,N- dimethyltryptamine in humans. I. Neuroendocrine, autonomic and cardiovascular effects. Archives of  General  Psychiatry. 51:85-97,
  7. Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Archives of General Psychiatry. 51:98-108,
  8. Strassman Hallucinogenic drugs in psychiatric research and treatment. Perspectives and prospects. Journal of Nervous and Mental Disease 183:127-138, 1995.
  9. Strassman RJ. Human psychopharmacology of N,N- dimethyltryptamine. Behavioral Brain  Research  73:121-124,
  10. Grob C, McKenna D, Callaway J, Brito G, Neves E, Oberlaender G, Saide O, Labigalini E, Tacla C, Miranda C, Strassman R, Boone K. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. Journal of  Nervous  and  Mental  Disease  184: 86-94,   1996
  11. Strassman RJ, Qualls C, Berg LM. Differential tolerance development to biological and subjective effects of four closely-spaced administrations of N,N-dimethyltryptamine in    Biological  Psychiatry  39:784-795, 1996
  12. Strassman RJ. Endogenous ketamine-like compounds and the NDE: If so, so what? Journal of Near-Death Studies 16:27-42, 1997
  13. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP. Psychedelic effects of ketamine in normal volunteers: Relationship to steady-state plasma concentrations. Anesthesiology 88:82- 88, 1998
  1. Riba J, Rodríguez-Fornelis A, Strassman RJ, Barbanoj M J. Psychometric assessment of the Hallucinogen Rating Scale in two different populations of hallucinogen users. Drug and Alcohol Dependence 62:215- 223, 2001
  2. Krupitsky EM, Burakov AM, Romanova TN, Grinenko AY, Strassman Ketamine-assisted psychotherapy (KTP) of heroin addiction: Immediate effects and six month follow-up. Heffter Review of Psychedelic Research 2:88-101, 2001
  3. Krupitsky EM, Burakov AM, Romanova TN, Dunaevksy I, Strassman RJ, Grinenko AY. Ketamine-assisted psychotherapy (KTP) of heroin addiction: Immediate effects and two-year follow-up. Journal of Substance Abuse Treatment 23:273-283, 2002
  4. Santos RG, Strassman RJ, Landeira-Fernandez J, Cruz Effects of ayahuasca on psychometric measures of anxiety, panic-like, and hopelessness in Santo Daime members. Journal of Ethnopharmacology 112:507-513, 2007
  5. McIlhenny EH, Pipkin KE, Standish LJ, Wechkin HA, Strassman RJ, Barker Direct analysis of psychoactive tryptamine and harmala alkaloids in the Amazonian botanical medicine ayahuasca by liquid chromatography- electrospray ionization-tandem mass spectrometry. Journal of Chromatography A  1216:8960-8968, 2009
  6. Barbosa PCR, Cazorla IM, Giglio JS, Strassman RJ. A prospective six-month evaluation of personality traits, psychiatric symptoms, and quality of life in ayahuasca-naïve subjects. Journal of Psychoactive Drugs 41:205- 212, 2009
  7. McIlhenny EH, Riba J, Barbanoj MJ, Strassman RJ, Barker Methodology for determining major constituents of ayahuasca and their metabolites in blood. Biomedical  Chromatography    25:970-984, 2011
  8. McIlhenny EH, Riba J, Barbanoj MJ, Strassman RJ, Barker SA. Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human Journal of  Chromatography  B   25:970-984,  2011
  9. Mizumoto S, Da Silveira DX, Barbosa PCR, Strassman RJ. Hallucinogen Rating Scale (HRS)- Versão Brasileira: tradução e adaptação transcultural (Hallucinogen Rating Scale [HRS]- A Brazilian version: translation and cross- cultural adaptation). Revista de Psiquiatria Clínica 38: 231-37, 2011
  10. Barker SA, McIlhenny EH, Strassman A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955- 2010. Drug  Testing  and  Analysis  4:617-635, 2012
  11. Barbosa PCR, Mizumoto S, Bogenschutz MP, Strassman Health status of ayahuasca users. Drug Testing and Analysis  4:601-609,  2012
  1. Barker SA, Borjigin J, Lomnicka I, Strassman LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate. Biomedical Chromatography 27:1690-1700, 2013
  2. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: A proof of concept study. Journal of Psychopharmacology  29 (3): 289-299, 2015
  3. Gallimore A, Strassman R. A model for the application of target- controlled intravenous infusion for a prolonged immersive DMT psychedelic experience. Frontiers  in  Pharmacology. doi:  3389/fphar.2016.00211. 2016
  4. Barbosa PCR, Strassman R, da Silveria DX, Areco K, Hoy R, Pommy J, Thomas R, Bogenschutz M. Psychological and neuropsychological assessment of regular hoasca users. Comprehensive Psychiatry 71:95-105, 2016
  5. Dean J, Liu T, Huff S, Sheler R, Barker SA, Strassman RJ, Wang M, Borjigin J. Biosynthesisand Extracellular Concentrationsof N,N-dimethyltryptamine (DMT) in Mammalian Brain. Scientific Reports10.1038/s41598-019-45812-w

Academic letters, editorials, and comments

  1. Santos RG, Strassman R: Ayahuasca and psychosis (electronic letter to the editor). British Journal of Psychiatry,
  2. Greer G, Strassman R: Information on “Ecstasy.” (letter) American Journal of Psychiatry 142:1391, 1985
  3. Strassman R Comment. Re: Rodriguez M. A Methodology for Studying Various Interpretations of the N,N-dimethyltryptamine-Induced Alternate Reality. Journal  of  Scientific  Exploration  21, 2007.
  4. Strassman R. Guest opinion. Should we loosen the restrictions on psychedelics? Scientific American, 2018.

Co-producer, DMT, The Spirit Molecule (documentary; Mitch Schultz filmmaker); Warner Bros. Distributing, 2011

  1. Strassman R. DMT: The Spirit Molecule. Rochester, VT: Park Street Press, 2001
  2. Strassman R, Wojtowicz S, Luna LE, Frecksa E. Inner Paths to Outer Space. Rochester VT: Park Street Press, 2008
  3. Strassman R. The Soul of Prophecy. Rochester, VT: Park Street Press, 2014
  4. Strassman R. Joseph Levy Escapes Death. Berkeley, CA: Regent Press, 2019.
Book chapters
  1. Lisansky EJ, Strassman RJ, Janowsky DS, Risch SC: Drug-induced psychoses. In: Tupin J, Halbreich U, Pena J (eds) Transient Psychosis: Diagnosis, Management, Evaluation. New York: Bruner/Mazel, 1984, pp. 80-110
  1. Strassman RJ. The pineal gland: Current evidence for its role in consciousness. In: Lyttle T (ed) Psychedelic Monographs and Essays. 5, Boynton Beach, FL; 1991, pp 166-205.
  2. Strassman RJ. Human hallucinogenic drug research: Regulatory, clinical and scientific issues. In: Lin G, Glennon RA (eds) Hallucinogens: An Update (NIDA Research Monograph 146), 1994, pp 92-123
  3. Strassman RJ. Human psychopharmacology of LSD, DMT and related compounds. In: Pletscher A (ed) 50 Years of LSD: State of the Art and Perspectives of Hallucinogens. London: Parthenon, 1994, pp. 145-174
  4. Strassman RJ. Biomedical research with psychedelics: Current models and future prospects. In: Forte R (ed) Entheogens and the Future of Religion. San Francisco: CSP; 1997, pp 153-164
  5. Strassman, RJ. Hallucinogens. In: Earleywine M (ed) Subjective Effects of Mind-Altering Drugs. New York: Oxford University Press. 2005, pp. 49-85
  6. Labate BC, Santos RG, Strassman RJ, Anderson B, Mizumoto, S. Efectos sobre la dependencia a sustanciasde de la pertenencia a una Iglesia Ayahuasquero Brasilena. In: Labate BC, Bouso JC (eds). Ayahuasca y Salud. Barcelona: Los Libros de la Liebre de Marzo. 2013, pp 302-310
  7. Labate BC, Santos RG, Strassman, RJ, Anderson B, Mizumoto S. Effect of Santo Daime membership on substance dependence. In: Labate BC, Bouso JC (eds). The Therapeutic Use of Ayahuasca. New York: Springer. 2013, 153-159 (English translation of #6 (above))
  8. Strassman R. Preparing for the journey. In: Hancock G (ed). The Divine Spark. San Francisco: Red Wheel/Weiser, 2015, 138-162 (reprint of chapter by the same name in Inner Paths to Outer Space [above]).
Lay Publications
  1. Strassman RJ, Sitting for sessions: Dharma & DMT Tricycle. The Buddhist  Review   6:81-88,1996
  2. Strassman RJ, Where to with psychedelic research? Asylum (A magazine for   democratic   psychiatry)  11:  4-6,
  3. Strassman RJ. Forward. In: Dobkin de Rios M, Janiger O LSD, Spirituality, and the Creative Process. Rochester, VT: Park Street Press; 2003, pp. ix-x.
  4. Strassman RJ, Creativity and psychedelics. Site Street. Arts and ideas (on-line journal), Spring 2003.
  5. Strassman RJ. The inner The Entheogen Review 15:77-80, 2006.
  6. Strassman Endogenous hallucinogens and bicamerality. The Jaynesian 3:13-16, 2009.
  7. Strassman Prophetic state and the DMT effect. Psychedelic Press UK. 5:18-28, 2014.
  8. Strassman R. Theoneurology: A New Model for Spiritual Edge Science 21:7-11, 2015.
  1. Strassman DMT and the Soul of Prophecy: An excerpt. Dragibus 3:14-18, 2015.
  1. Strassman Prophetic experience and the DMT effect. Watkins Mind, Body,  Spirit  42: 34-36, 2015.
  1. American College of Neuropsychopharmacology (1991): Workshop on Human Effects of Melatonin (Alfred J. Lewy, M.D., Ph.D. chair)
  2. American Psychiatric Association (1993): Clinical Research with Hallucinogens (Charles Grob, M.D. co-presenter)
  3. Serotonin Club (Satellite Meeting of IUPHAR Annual Meeting) (1994): Clinical Research with Hallucinogens (Chair)
  4. CINP Annual Meeting (1994): Human Hallucinogen Research (Co- Chair, with Mark A. Geyer, D.)
  1. Strassman R, Peake G, Lisansky E, Uhlenhuth E: Constant nocturnal light suppresses melatonin secretion all night in man. American College of Neuropsychopharmacology Annual Meeting, Washington, DC, 1986
  2. Strassman R, Peake G, Lisansky E: A model for the study of melatonin in man: All-night suppression with bright light and subsequent replacement in a physiological range. National Institute of Health General Clinical Research Centers Annual Meeting, Williamsburg, VA, 1987
  3. Strassman R, Peake G, Qualls C, Lewy A: Human melatonin: No effect on acute regulation of nocturnal TSH and cortisol secretion. American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico, 1987
  4. Strassman R, Qualls C, Uhlenhuth E, Kellner R: Human psychopharmacology and neuroendocrinology of DMT. American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico, 1991
  5. Strassman R, Qualls C, Uhlenhuth E. Human tolerance studies with the hallucinogen, N,N-dimethyltryptamine. American College of Neuropsychopharmacology, Honolulu, Hawaii,
Book reviews
  1. Hofmann A: LSD, My Problem Child: Reflections on Sacred Drugs, Mysticism, and Science. Am J  Psychiatry  141:1626-1628,  1984
  2. Leary T: Flashbacks: An Autobiography. Am J Psychiatry 141:1626-1628, 1984
  1. Bakalar J, Grinspoon L: Drug Control in a Free Society. JAMA 254:2974-2975, 1985
  1. Grinspoon L, Bakalar J (Eds): Psychedelic Am J Psychiatry 143:249-250, 1986
  1. Dobkin de Rios M: Hallucinogens: Cross-Cultural Psychiatry  50:90-93, 1987
  1. Westermeyer J: A Clinical Guide of Alcohol and Drug J Clin Psychiatry 48:421, 1987
  2. Levy S, Blume S (Eds): Addictions in the Jewish Am J Psychiatry 145:121-122, 1988
  3. Herrington R, Jacobson G, Benzer D (Eds): Alcohol and Drug Abuse Handbook. J Clin Psychiatry 49:123-124, 1988
  4. Milkman H, Sunderwirth S: Craving for Ecstasy: The Consciousness and Chemistry of Escape. JAMA 259:2614-2615, 1988
  5. Hendin H, Haas A, Singer P, Ellner M, Ulman R: Living High: Daily Marijuana Use Among Adults. Am J  Psychiatry  145:1467-1468,  1988
  6. Fisher S, Raskin A, Uhlenhuth EH (Eds): Cocaine: Clinical and Biobehavioral Aspects. J  Clin  Psychiatry  49:328, 1988
  7. Jacobs MR, Fehr KOB (Eds): Drugs and Drug Abuse, 2nd J Clin Psychiatry  49:375, 1988
  8. Levinthal CF: Messengers of Paradise: Opiates and the Brain. JAMA 260:3350-3351, 1988
  1. Halaris A: Chronobiology and Psychiatric Am J Psychiatry 146:113-114, 1989
  1. Lee MA, Shlain B: Acid Am J Psychiatry 146:395-396, 1989
  2. Stevens J: Storming Heaven. Am J Psychiatry 146:395-396, 1989
  3. Nace EP: The Treatment of Alcoholism. J Clin Psychiatry 50:74-75, 1989
  4. Frances RJ, Miller SI: Clinical Textbook of Addictive J Clin Psychiatry 52:435, 1991
  5. Grinspoon L, Bakalar J: Marijuana: Forbidden Medicine. JAMA 270:2878-2879, 1993
  1. McKenna T: Food of the Gods. Network (The Scientific and Medical Network Newsletter)  53:58-59, 1994
  2. Stafford P: Psychedelics Encyclopedia, 3rd Am J Addict 3:178- 180, 1994
  3. Mancall PC: Deadly Medicine: Indians and Alcohol in Early JAMA 275:646-647, 1996
  1. Zimmer L, Morgan JP: Marijuana Myths, Marijuana facts: A Review of the Scientific JAMA 279:632-633, 1998
  2. Grinspoon L, Bakalar JB: Marihuana: Forbidden Medicine (rev. ). JAMA 279:963-964, 1998
  1. Devereuex P: The Long Trip. Network 69:63-64, 1999
  2. Kharitidi O: Entering the Circle. Journal of Scientific Exploration 18:497-500, 2004
  3. Richards W. Sacred Knowledge. Journal of Psychedelic Studies, 2018. DOI: 10.1556/2054.2018.003